Kilitch Drugs (India) Ltd
₹ 182
0.20%
29 May
- close price
About
Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products[1]
Key Points
- Market Cap ₹ 640 Cr.
- Current Price ₹ 182
- High / Low ₹ 250 / 117
- Stock P/E 19.8
- Book Value ₹ 95.2
- Dividend Yield 0.00 %
- ROCE 12.2 %
- ROE 11.1 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 44.1% CAGR over last 5 years
- Company's median sales growth is 21.4% of last 10 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 10.2% over last 3 years.
- Earnings include an other income of Rs.13.8 Cr.
- Company has high debtors of 227 days.
- Promoter holding has decreased over last 3 years: -4.48%
- Working capital days have increased from 84.5 days to 172 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19 | 21 | 27 | 50 | 96 | 61 | 70 | 105 | 118 | 132 | 182 | 189 | |
| 21 | 24 | 27 | 44 | 79 | 59 | 65 | 94 | 100 | 111 | 150 | 156 | |
| Operating Profit | -2 | -3 | -0 | 6 | 17 | 2 | 5 | 11 | 17 | 20 | 31 | 32 |
| OPM % | -9% | -15% | -0% | 12% | 18% | 3% | 8% | 11% | 15% | 16% | 17% | 17% |
| 3 | 2 | 1 | 3 | 4 | 6 | 4 | 5 | 5 | 6 | 14 | 14 | |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Depreciation | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | -1 | -2 | -0 | 7 | 20 | 5 | 8 | 14 | 19 | 23 | 41 | 42 |
| Tax % | -79% | -18% | -91% | 13% | 24% | 15% | 18% | 24% | 19% | 25% | 23% | 22% |
| -0 | -2 | -0 | 6 | 15 | 4 | 6 | 11 | 16 | 18 | 31 | 32 | |
| EPS in Rs | -0.07 | -0.71 | -0.01 | 2.07 | 4.42 | 1.33 | 1.83 | 3.11 | 4.64 | 5.02 | 8.90 | 9.27 |
| Dividend Payout % | 0% | 0% | 0% | 11% | 5% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 22% |
| 3 Years: | 17% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 36% |
| 5 Years: | 44% |
| 3 Years: | 29% |
| TTM: | 24% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 17% |
| 3 Years: | 22% |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 9% |
| 3 Years: | 10% |
| Last Year: | 11% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 14 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 35 |
| Reserves | 107 | 105 | 106 | 117 | 136 | 136 | 147 | 162 | 180 | 207 | 237 | 298 |
| 0 | 0 | 1 | 1 | 9 | 13 | 15 | 20 | 22 | 31 | 49 | 88 | |
| 7 | 8 | 10 | 13 | 12 | 10 | 18 | 34 | 35 | 33 | 56 | 78 | |
| Total Liabilities | 127 | 126 | 130 | 145 | 172 | 174 | 196 | 232 | 252 | 287 | 358 | 499 |
| 9 | 8 | 8 | 7 | 8 | 8 | 7 | 14 | 15 | 16 | 20 | 20 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 47 | 140 |
| Investments | 72 | 92 | 96 | 101 | 100 | 98 | 106 | 117 | 110 | 121 | 121 | 124 |
| 46 | 25 | 26 | 37 | 65 | 68 | 82 | 101 | 126 | 145 | 170 | 216 | |
| Total Assets | 127 | 126 | 130 | 145 | 172 | 174 | 196 | 232 | 252 | 287 | 358 | 499 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8 | 18 | 1 | -1 | 7 | 7 | 6 | 5 | 6 | -3 | 15 | 12 | |
| -31 | -20 | -1 | -2 | -22 | -10 | -5 | -16 | 6 | -9 | -41 | -96 | |
| -0 | -0 | -0 | 6 | 15 | 1 | 2 | 8 | 3 | 11 | 16 | 86 | |
| Net Cash Flow | -39 | -2 | -0 | 2 | 0 | -1 | 3 | -3 | 15 | 0 | -11 | 2 |
| Free Cash Flow | -10 | 17 | -0 | -2 | 6 | 6 | 6 | -3 | 3 | -9 | -32 | -83 |
| CFO/OP | 464% | -569% | -400% | -22% | 68% | 596% | 134% | 70% | 60% | 22% | 76% | 70% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 243 | 285 | 200 | 150 | 88 | 102 | 120 | 144 | 165 | 171 | 168 | 227 |
| Inventory Days | 124 | 110 | 84 | 39 | 33 | 57 | 34 | 30 | 13 | 22 | 61 | 47 |
| Days Payable | 123 | 152 | 183 | 108 | 38 | 81 | 127 | 168 | 180 | 144 | 188 | 280 |
| Cash Conversion Cycle | 244 | 243 | 101 | 82 | 83 | 78 | 27 | 6 | -3 | 49 | 40 | -6 |
| Working Capital Days | 196 | 230 | 122 | 98 | 42 | 20 | -15 | -21 | 4 | 25 | 57 | 172 |
| ROCE % | -1% | -2% | -0% | 5% | 12% | 3% | 4% | 7% | 9% | 10% | 13% | 12% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Export Registration Expenditure INR Lakhs |
|
|||||||||||
| Ethiopia Cephalosporin Capacity Utilization % |
||||||||||||
| Number of Product Registrations (Global) Count |
||||||||||||
| Number of Countries Exported To Count |
||||||||||||
| Products Under Registration Count |
||||||||||||
| Order Book (Ethiopia Government Tender) USD Million |
||||||||||||
| Employee Strength (Plants and Offices) Count |
||||||||||||
| Khopoli Planned Capacity: Liquid Injectable Ampoules Million Units per year |
||||||||||||
| Khopoli Planned Capacity: Liquid Injectable Vials Million Units per year |
||||||||||||
| Khopoli Planned Capacity: Ophthalmic/Nasal Drops Million Units per year |
||||||||||||
| Khopoli Planned Capacity: Oral Tablets Million Units per year |
||||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
2d - Annual secretarial compliance report for FY2026 noted two ₹11,800 fines for delayed board meeting intimation.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
18 May - We are submitting hereby copy of newspaper publication of the extract of financial results for the quarter ended 31st March, 2026
-
Board Meeting Outcome for Submission Of Audited Standalone And Consolidated Financial Results For The Quarter Ended 31St March, 2026
15 May - Kilitch Drugs approved FY26 standalone and consolidated audited results; unmodified audit opinion, 1:1 bonus shares allotted.
-
Audited Standalone And Consolidated Financial Results For The Quarter Ended 31St March, 2026
15 May - Board approved audited standalone and consolidated FY26 results on 15 May 2026; auditors issued unmodified opinion.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
15 May - Infomerics report for quarter ended 31 Mar 2026 found no deviation; Rs1.12 crore GCP unutilized.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Jun 2024TranscriptPPT
-
Jun 2023TranscriptPPT
Business Overview:[1]
KDL is a pharmaceutical company engaged in developing, manufacturing, marketing, and exporting various Pharmaceutical Formulations in dosage forms like Solid, Liquid, and Parental.